In breast cancer survivors treated with TZ and AC, 25% experienced long-term LVSD; comprehensive CV risk assessments and regular monitoring are essential for managing elevated NT-proBNP, hs-cTnT, and lipid levels. This evidence concerns the gene TNNT2 and breast cancer.